Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22526

Shown on this page

Current sort

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

MD Anderson Cancer Center

Live official records

Open in full search

Conditions: Neoplasms, Tenosynovial Giant Cell Tumor
Interventions: ABSK021; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 4
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 1 more

Conditions: Heterozygous Familial Hypercholesterolaemia
Interventions: AZD0780, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis, MASH
Interventions: ALN-CIDEB, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Tucson, Arizona • Pasadena, California • Rialto, California + 16 more

Conditions: Cystic Fibrosis-related Diabetes
Interventions: iLet Bionic Pancreas System (BP), Usual Care (UC); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 14 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more

Conditions: Breast Cancer, Metastatic
Interventions: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 38 more

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Autoinjector; Drug · Device
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: San Diego, California • Miami, Florida • Orlando, Florida + 17 more

Conditions: Intracranial Meningioma
Interventions: [177Lu]Lu-DOTATATE, Standard of Care treatments; Drug · Other
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 18
States / cities: Irvine, California • La Jolla, California • New Haven, Connecticut + 14 more

Conditions: Breast Reconstruction After Mastectomy
Interventions: NRI implantation; Device
Lead sponsor: FixNip Ltd; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Cetuximab, Computed Tomography, Echocardiography Test, Encorafenib, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Irvine, California • Los Angeles, California + 12 more

Conditions: Autoimmunity, Inflammation
Interventions: Secukinumab s.c. injection; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 28
States / cities: Fullerton, California • La Mesa, California • San Leandro, California + 25 more

Conditions: Metabolic Dysfunction-associated Steatohepatitis
Interventions: Placebo, ECC4703, ECC0509; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 70
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 59 more

Clinical trials in Houston, Texas

Filter and sort this location

Institutions in Houston

Live official records

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Bionic Pancreas in CFRD

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

PREFIX FEASIBILITY Study - PRojection & Safety Evaluation of the FIXNip Nipple Reconstruction Implant

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Secukinumab Open Label Roll-over Extension Protocol

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)